Board

Christopher Adam
Christopher Adam has over 35 years of board level and operational experience in the pharmaceutical industry, including executive roles in the mergers of Glaxo with Wellcome, and in the acquisition of biotechs such as Affymax. He has sat on the executive committee of Glaxo Wellcome, the board of Glaxo Group Research, and at various times has served as President and CEO of Glaxo's Japanese and French operations. Amongst other senior posts at Glaxo, he has held the positions of Director of Commercial Strategy, and Director of International Marketing. Mr Adam holds a BSc in Biochemistry from University College London, an EMBA from Stanford Business School and is a Chevalier de la Légion d'Honneur, commended for services to the healthcare industry.

Dr Yen Choo
Dr Choo is the Founder and Chief Executive of Plasticell. He was a Founder and Chief Scientist of Gendaq Ltd, an MRC gene regulation company which was acquired by US biotech Sangamo Biosciences Inc. (Richmond, CA). Previously Dr Choo was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge. He is an inventor named in over 15 granted patents and has published over 30 scientific papers, holds a PhD in Molecular Biology from the University of Cambridge and is the recipient of the Prize for Young Scientists awarded by Pharmacia Biotech and Science the pre-eminent international scientific journal.

Hugh Cochrane
Hugh Cochrane is CEO of Villay Asset Management, an investment consultancy specializing in UK and European venture capital as well as investment in European equities. He has a history of investing in successful technology companies at an early stage and longstanding personal experience of managing start-up enterprises.

Daniel Green
Daniel Green is Managing Partner of DJG Advisors LLP and a Venture Partner at HBM Partners, both investment advisory services specializing in the global life sciences sector. Previously, he was Director at Dresdner Kleinwort Wasserstein where he co-managed the private equity fund DrKC Life Science Partners LP, and before that at the Medical Research Council's venture capital subsidiary MVM Ltd. Formerly, Mr Green was Pharmaceuticals and Biotechnology Correspondent of the Financial Times. He has served on the boards of various biotechnology companies including Cyclacel, Exonhit Therapeutics, Inpharmatica, Gendaq, Zycos, Predix and Scimagic.